Trade

with

Novo-Nordisk A/S
(NYSE: NVO)
AdChoices
45.34
-0.09
-0.20%
Pre-Market :
45.70
+0.36
+0.79%

Open

45.77

Previous Close

45.43

Volume (Avg)

1.37M (1.08M)

Day's Range

45.31-46.03

52Wk Range

33.04-49.11

Market Cap.

124.93B

Dividend Rate (Yield )

0.61 (1.33%)

Beta

0.97

Shares Outstanding

2.75B

P/E Ratio (EPS)

27.10 (1.66)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Underperform
    • Revenue

    • 14.28B

    • Net Income

    • 4.30B

    • Market Cap.

    • 124.93B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 30.79

    • PEG (Price/Earnings Growth) Ratio

    • 2.41

    • Beta

    • 0.97

    • Forward P/E

    • 23.98

    • Price/Sales

    • 8.39

    • Price/Book Value

    • 19.92

    • Price/Cash flow

    • 29.59

      • EBITDA

      • 6.05B

      • Return on Capital %

      • 40.51

      • Return on Equity %

      • 71.98

      • Return on Assets %

      • 40.51

      • Book Value/Share

      • 0.39

      • Shares Outstanding

      • 2.75B

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.61 (3/21/2014)

      • Dividend Declaration Date

      • 3/26/2014

      Analyst Recommendation
      10/21/2014
      Underperform
        • 1 Year Price Target

        • 38.70

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • 1.81

        • Cashflow Estimate

        • 2.06

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 1.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 17.50

          • 17.04

          • Net Income

            Q/Q (last year)

          • 3.90

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 12.85

          • 63.43

          • Net Income

            5-Year Annual Average

          • 21.10

          • 10.65

          • Dividends

            5-Year Annual Average

          • 32.69

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 83.30

            • 82.75

            • Pre-Tax Margin

            • 39.65

            • 39.38

            • Net Profit Margin

            • 30.79

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 81.40

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 33.00

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 25.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 1.44

              • 2.92

              • Quick Ratio

              • 0.98

              • 2.35

              • Interest Coverage

              • 242.88

              • 38.02

              • Leverage Ratio

              • 1.74

              • 2.21

              • Book Value/Share

              • 2.29

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 27.10

                • 277.78

                • P/E Ratio 5-Year High

                • 29.33

                • 634.30

                • P/E Ratio 5-Year Low

                • 7.38

                • 124.82

                • Price/Sales Ratio

                • 8.35

                • 9.35

                • Price/Book Value

                • 19.84

                • 8.50

                • Price/Cash Flow Ratio

                • 29.59

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 71.98

                    (46.50)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 40.51

                    (28.50)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 71.17

                    (47.60)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 703.37k

                  • 117.08k

                  • Inventory Turnover

                  • 1.38

                  • 1.48

                  • Asset Turnover

                  • 1.32

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  5.38B
                  Operating Margin
                  37.68
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  29.59
                  Ownership

                  Institutional Ownership

                  7.26%

                  Top 10 Institutions

                  3.93%

                  Mutual Fund Ownership

                  2.21%

                  Float

                  -

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Harbor Capital Appreciation Fund

                  •  

                    10,388,431

                  • 4.28

                  • 0.38

                  • Fidelity® Series International Growth

                  •  

                    7,326,230

                  • 0.00

                  • 0.27

                  • Dreyfus Appreciation Fund

                  •  

                    2,656,500

                  • 0.00

                  • 0.10

                  • Delaware U.S. Growth Fund

                  •  

                    2,084,800

                  • 9.34

                  • 0.08

                  • Delaware Large Cap Growth Collective Investment Trust

                  •  

                    2,084,800

                  • 9.34

                  • 0.08

                  • Scout International Fund

                  •  

                    1,783,635

                  • 0.00

                  • 0.06

                  • Goldman Sachs Rising Dividend Growth

                  •  

                    1,653,600

                  • 5.39

                  • 0.06

                  • Vanguard U.S. Growth Portfolio

                  •  

                    1,487,733

                  • 0.00

                  • 0.05

                  • AST Marsico Capital Growth

                  •  

                    1,436,203

                  • -1.32

                  • 0.05

                  • OPPENHEIMER Rising Dividends Fund

                  •  

                    1,328,650

                  • 101.33

                  • 0.05

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Jennison Associates LLC

                  •  

                    26,895,047

                  • +1.36%

                  • 0.98

                  • Renaissance Technologies Corp

                  •  

                    16,953,000

                  • +5.43%

                  • 0.62

                  • Fisher Asset Management, LLC

                  •  

                    13,385,913

                  • -2.59%

                  • 0.49

                  • Fidelity Management and Research Company

                  •  

                    10,697,204

                  • +5.42%

                  • 0.39

                  • Columbia Management Company

                  •  

                    8,731,965

                  • +1.21%

                  • 0.32

                  • Fayez Sarofim & Company

                  •  

                    6,770,540

                  • -3.48%

                  • 0.25

                  • Loomis Sayles & Company L.P.

                  •  

                    4,186,738

                  • +7.28%

                  • 0.15

                  • WCM Investment Management

                  •  

                    4,180,732

                  • +36.19%

                  • 0.15

                  • Managed Account Advisors LLC

                  •  

                    4,171,284

                  • -0.21%

                  • 0.15

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Classic Growth

                  Style

                  Large Growth

                  Novo-Nordisk A/S was incorporated on 28th November, 1931 in Denmark. It is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products which include glucagon, protein-related delivery systems and needles, obesity and oral antidiabetic drugs. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy, hormone replacement therapy and inflammation.

                  Key People

                  Mr. Lars Rebien Sorensen

                  CEO/President

                  Dr. Goran A. Ando,,M.D.

                  Director/Chairman of the Board

                  Mr. Jeppe Christiansen

                  Director/Vice Chairman of the Board

                  Mr. Jesper Brandgaard

                  CFO/Executive VP

                  Mr. Lars Fruergaard Jorgensen

                  Chief Information Officer/Executive VP

                  • Novo-Nordisk A/S

                  • Novo Allé

                  • Bagsværd, 2880

                  • DNK.Map

                  • Phone: +45 44448888

                  • Fax: +45 44490555

                  • novonordisk.com

                  Incorporated

                  1931

                  Employees

                  36,851

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: